Table 2

Crude incidence rates and hazard rates of verified first VTE in nbDMARD and anti-TNF-treated patients

nbDMARD n=3673Anti-TNF n=11 881ETN n=4139INF n=3475ADA n=4267
Exposure (person years)11 42441 23517 97710 48412 773
Total VTEs, n45151604942
VTE incidence rate/1000 person years (95% CI)3.9 (2.9 to 5.3)3.7 (3.1 to 4.3)3.3 (2.5 to 4.3)4.7 (3.5 6.2)3.3 (2.4 to 4.4)
Unadjusted HR (95% CI)Ref1.1 (0.8 to 1.6)1.0 (0.7 to 1.6)1.4 (0.9 to 2.1)1.0 (0.6 to 1.5)
Adjusted HR (95% CI)*Ref0.8 (0.5 to 1.5)0.8 (0.4 to 1.4)1.1 (0.6 to 1.9)0.8 (0.4 to 1.4)
  • ADA, adalimumab; Anti-TNF, anti-tumour necrosis factor; ETN, etanercept; INF, infliximab; nbDMARD, non-biological disease-modifying antirheumatic drug; VTE, venous thrombotic event.

  • * Inverse probability of treatment weighting model adjusted for age, gender, diabetes, baseline steroid exposure, smoking, hypertension, disease duration, disease severity, year of first anti-TNF drug and year of entry into study, with surgery as a time-varying covariate.

  • Differences between INF and ETN rates were non-significant (p=0.186). Differences between INF and ADA rates were non-significant (p=0.105).